PCRX חוב כולל להון Pacira Corp

The financing structure chart (debt-to-equity) helps assess the resilience of Pacira BioSciences (PCRX) to EXPAREL generic competition and regulatory challenges. The company is currently integrating acquired assets to expand its portfolio, relying on stable demand for surgery despite the moderate cyclicality of elective procedures. The value 0.57 represents the latest measurement of the business's leverage relative to its equity.

Scaling the EXPAREL non-opioid pain management system requires significant capital expenditures for surgeon training and the implementation of B2B protocols. The metric is calculated as the ratio of total liabilities to net shareholders' equity. This ratio determines the business's dependence on debt financing and the associated debt service risks. An increase in this indicator signals higher financial leverage and potential vulnerability to interest rates. By analyzing the total debt-to-equity ratio, an investor assesses the stability of the balance sheet structure for Pacira BioSciences (PCRX).